Table 3.
Clinical characteristics according to PIK3CA mutation status in lung adenocarcinoma
| Total (n = 122) N (%) |
PIK3CA mutation status
|
Pa | ||
|---|---|---|---|---|
| Wild-type (n = 98) N (%) | Mutant (n = 24) N (%) | |||
| Age (years) | ||||
| Mean (range) | 60 (36–83) | 61 (37–83) | 58 (36–73) | |
| 0–60 | 60 (49%) | 46 (47%) | 14 (58%) | 0.32 |
| >60 | 62 (51%) | 52 (53%) | 10 (42%) | |
| Lymph node status | ||||
| Ln (−) | 52 (43%) | 47 (48%) | 5 (21%) | 0.029b |
| Ln (+) | 70 (57%) | 51 (52%) | 19 (79%) | |
| Distant metastasis | ||||
| M (−) | 111 (91%) | 89 (91%) | 22 (92%) | 0.79 |
| M (+) | 11 (9%) | 9 (9%) | 2 (8%) | |
| Clinicopathologic stage | ||||
| I–II | 50 (41%) | 44 (45%) | 6 (25%) | 0.122 |
| III–IV | 72 (59%) | 54 (55%) | 18 (75%) | |
| Smoking status | ||||
| Smoker | 59 (48%) | 47 (48%) | 12 (50%) | 0.78 |
| Nonsmoker | 60 (49%) | 49 (50%) | 11 (46%) | |
| Missing | 3 (2%) | 2 (2%) | 1 (4%) | |
Notes:
a
χ2 test used for binary/categorical variables;
b
P < 0.05.
Abbreviations: Ln, lymph node; M, metastasis.